Sign up to save your podcasts
Or
Share FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.
Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including:
• The significance of the study in the context of recent FDA approvals and treatment advancements.
• Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab.
• The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes.
• Management of side effects and clinical pearls for practitioners.
We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions.
Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, share, and subscribe for more practice-changing updates in oncology!
#MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.
Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including:
• The significance of the study in the context of recent FDA approvals and treatment advancements.
• Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab.
• The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes.
• Management of side effects and clinical pearls for practitioners.
We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions.
Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, share, and subscribe for more practice-changing updates in oncology!
#MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
58 Listeners
Mayo Clinic Talks
297 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,357 Listeners
Core IM | Internal Medicine Podcast
1,142 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners